Page 78 - QueenAwardsMagazine2017

PROOF OF ENTR Y IN THE QUEEN’S AWARD MAGAZINE
to check the entry and confirm that it is either passed for press, or provide clear instructions if amendments are required. You are very welcome to email your comments to us at ian. blaza@queensawardsmagazine. com
LOGO for an enhanced entry in the Index of Contributors
If you have also ordered an enhanced entry to be placed in the Index of Contributors, then a proof of your logo is shown here on the right. Note that, for technical reasons, the size of entry in the printed product may vary slightly from that shown here. This option will also include your full contact details, as used on the editorial entry and proofed below here.
20 1 7 (this is our preferred option) or else you can
We have produced the following editorial to the best of our understanding of your require-
ments, and using the text & materials you have kindly supplied to us. Would you please care
call us on 01536 520654
Company Description in the ‘List of Winners’ preceeding the section, for checking:
SYNE QUA NON LTD (SQN)
Specialist clinical biometrics CRO supporting pharma, biotech, medical device and animal health partners with innovative clinical development services
Syne Qua Non Ltd (SQN)
SYNE QUA NON LIMITED (SQN) is one of the world’s recognised specialist clinical biometrics CROs supporting global pharma, biotech, medical device and animal health partners with innovative clinical development services.
SQN was previously honoured with a Queen’s Award for Enterprise in 2009, in the international trade category in recognition of our business growth and export performance. SQN is extremely proud to have won the 2017 Queen’s Award for Innovation for Syne-clin, our innovative EDC and Trial Management system. This award is doubly signi cant for SQN and our sta .
Syne-clin is an innovative, internet and mobile device based, real-time system for collecting, assessing and reporting patient data from clinical trials supporting new clinical treatment options within the healthcare industry.
Utilising standard validated library elements
to build each study system, Syne-clin delivers signi cant time and cost savings and shortens the drug development cycle, accelerating the process of getting new medical treatments to market.
Incorporating mobile, tablet and smartphone device data collection, Syne-clin allows real-time collection of patient clinical outcomes utilising electronic diary and questionnaire functionality. Prompts within the system ensure compliance and greatly enhance patient engagement with their own treatment path. Additionally, these data-driven alerts further enhance patient safety, such as when prescribing additional medication, where potential drug-drug interaction risks are agged, reducing the risk of contra-indicated drugs being administered to patients and
Syne-clin is an innovative, internet and mobile device based, real-time system for collecting, assessing and reporting patient data.
SQN’s Directors, Tony Rees and Karen Grover meeting Her Majesty The Queen on receiving their rst Queen’s Award in 2009.
the risks this can present. The rapid reporting of drug-related adverse events is accommodated and exceeds statutory timelines laid down by
national and international government guidelines. External data, medical
imaging and uniquely, diagrammatic data collection functionality add signi cant value
to trial designs. This functionality has been instrumental in supporting unique trial designs that could not have been accommodated without this support.
In addition, the ability to include multiple language live-switching within the system means that only one system is required
per study, regardless of
the site locations, and site clinical trial experience. Users have access to their
data in their own language.
While updates and amendments can be rolled
out on a country or site-speci c basis, generally all users are interacting with one system, meaning that system downtime is virtually zero. This
functionality has supported marketing and system di erentiation and helped gain new business from overseas companies requiring their local language support.
Our technology and innovation project has also allowed SQN to successfully compete internationally and win clinical research projects from overseas competition thus supporting and enhancing the reputation of the UK as a centre of excellence for pharmaceutical and healthcare research.
This trend continues as the rapid and ongoing development of mobile and wearable devices creates opportunities to collect patient
data in ways previously not possible. Our technology incorporates these developments and allows enhanced functionality and added value.
Current and future developments will allow us to continue to increase market share
and generate new business opportunities.
The Queen’s Award re ects our unprecedented success to date, and invigorates our ambitions for the future.
SYNE QUA NON L TD
Gostling House, Diss Business Park, Diss, Norfolk IP22 4GT Tel: +44 (0) 1379 644 449 • Fax: +44 (0)1379 644 445 Info@synequanon.com • www.synequanon.com
@synequanon @synequanon Syne qua non
www.queensawardsmagazine.com
Please note that the final layout of this material may vary slighty from that shown here, to suit the final design of the page it is included on. No further proofs will be sent after approval unless requested. This proof is supplied in
a format and resolution suitable for email; if you require a high-resolution version, or would prefer it in an alternative format - such as a JPG image – then please contact us on ian.blaza@queensawardmagazine.com
78